Cat. No. 3107
Chemical Name: N-methyl-N-[3-[4-(phenylmethyl)phen
Biological ActivityPotent and selective inhibitor of LTA4 hydrolase. Does not inhibit other enzymes of the arachidonic acid cascade including COX-1, COX-2, LTC4 synthase and 5-lipoxygenase. Potently inhibits LTB4 production in whole blood (IC50 = 49 nM). Orally active.
Licensing InformationSold for research purposes under agreement from Pfizer Inc.
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Certificate of Analysis / Safety Data Sheet
Askonas et al (2002) Pharmacological characterization of SC-57461A (3-[methyl[3-[4-(phenylmethyl)phenoxy]propyl]amino]propanoic acid HCl), a potent and selective inhibitor of leukotriene A4 hydrolase I: in vitro studies. J.Pharmacol.Exp.Ther. 300 577. PMID: 11805219.
Kachur et al (2002) Pharmacological characterization of SC-57461A (3-[methyl[3-[4-(phenylmethyl)phenoxy]propyl]amino]propanoic acid HCl), a potent and selective inhibitor of leukotriene A4 hydrolase II: in vivo studies. J.Pharmacol.Exp.Ther. 300 583. PMID: 11805220.
Penning et al (2002) Synthesis of potent leukotriene A4 hydrolase inhibitors. Identification of 3-[methyl[3-[4-(phenylmethyl)phenoxy]propyl]amino]propanoic acid. J.Med.Chem. 45 3482. PMID: 12139459.
If you know of a relevant reference for this product please let us know.
Citations are publications that use Tocris products.
Do you know of a great paper that uses SC 57461A from Tocris? If so please let us know.
View Related Products by Product Action
Keywords: SC 57461A, supplier, Selective, inhibitors, inhibits, LTA4, hydrolases, SC57461A, Pfizer, Tocris Bioscience, LTA4 Hydrolase Inhibitor products
Find multiple products by catalog number
New Products in this Area
Potent soluble epoxide hydrolase inhibitor; orally bioavailable and brain penetrantJZP 430
Potent and irreversible α/β-hydrolase domain 6 (ABHD6) inhibitorBPTES
Selective allosteric glutaminase (GLS1) inhibitor
November 12 - 16, 2016
San Diego, CA, USA